Radiation oncology society adopts new moniker

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 2
Volume 18
Issue 2

The American Society for Therapeutic Radiology and Oncology (ASTRO) has changed its name to the American Society for Radiation Oncology, but will continue to use the “T’ in its logo as part of its tagline “Targeting Cancer Care.”

The American Society for Therapeutic Radiology and Oncology (ASTRO) has changed its name to the American Society for Radiation Oncology, but will continue to use the “T’ in its logo as part of its tagline “Targeting Cancer Care.”

“Over the past few decades the term ‘therapeutic radiology’ has become outdated and confusing as radiation oncology has evolved into a specialty very separate from its origins in diagnostic radiology,” said Laura I. Thevenot, the society’s CEO.

“ASTRO’s new name will better correlate with the term that our members are using in their own practices to communicate with patients and better reflect who we are as a specialty,” she said. This is the fourth time the society has changed its name since it was established as the American Club of Therapeutic Radiologists in 1958.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.